Answers are grounded in this paper and cite their sources.
846–854. Ross, D.M., Branford, S., Seymour, J.F., Schwarer, A.P., Arthur, C., Yeung, D.T., Dang, P., Goyne, J.M., Slader, C., Filshie, R.J., Mills, A.K., Melo, J.V., White, D.L., Grigg, A.P. & Hughes, T.P. (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 122, 515–522. Rousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F.E., Varet, B., Gardembas, M., Etienne, G., Rea, D., Roy, L., Escoffre-Barbe, M., Guerci-Bresler, A., Tulliez, M., Prost, S., Spentchian, M., Cayuela, J.M., Reiffers, J., Chomel, J.C., Turhan, A., Guilhot, J., Guilhot, F. & Mahon, F.X. (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Journal of Clinical Oncology, 32, 424–430. Saussele, S., Richter, J., Guilhot, J., Gruber, F.X., Hjorth-Hansen, H., Almeida, A., Janssen, J.J.W.M., Mayer, J., Koskenvesa, P., Panayiotidis, P., Olsson-Stromberg, U., Martinez-Lopez, J., Rousselot, P., Vestergaard, H., Ehrencrona, H., Kairisto, V., Machova, P.K., Muller, M.C., Mustjoki, S., Berger, M.G., Fabarius, A., Hofmann, W.K., Hochhaus, A., Pfirrmann, M. & Mahon, F.X. (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. The Lancet Oncology, 19, 747–757.
No takes yet. Share an insight, caveat, or question.
Biron‐Andréani et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: